Ideation and implementation of an open science drug discovery business model – M4K Pharma
Open Access
- 6 December 2018
- journal article
- Published by F1000 Research Ltd in Wellcome Open Research
Abstract
M4K Pharma was incorporated to launch an open science drug discovery program that relies on regulatory exclusivity as its primary intellectual property and commercial asset, in lieu of patents.In many cases and in key markets, using regulatory exclusivity can provide equivalent commercial protection to patents, while also being compatible with open science. The model is proving attractive to government, foundation and individual funders, who collectively have different expectations for returns on investment compared with biotech, pharmaceutical companies, or venture capital investors.In the absence of these investor-driven requirements for returns, it should be possible to commercialize therapeutics at affordable prices.M4K is piloting this open science business model in a rare paediatric brain tumour, but there is no reason it should not be more widely applicable.Funding Information
- Ontario Institute for Cancer Research
- Brain Tumour Charity
- Wellcome Trust (106169)
- Structural Genomics Consortium
This publication has 37 references indexed in Scilit:
- ACVR1 Mutations in DIPG: Lessons Learned from FOPCancer Research, 2014
- The Pediatric Studies Initiative: After 15 Years Have We Reached the Limits of the Law?Clinical Therapeutics, 2014
- Where do new medicines originate from in the EU?Nature Reviews Drug Discovery, 2014
- Asia's Ascent — Global Trends in Biomedical R&D ExpendituresThe New England Journal of Medicine, 2014
- Pricing for Orphan DrugsJAMA, 2013
- The story of artesunate–mefloquine (ASMQ), innovative partnerships in drug development: case studyMalaria Journal, 2013
- Diagnosing the decline in pharmaceutical R&D efficiencyNature Reviews Drug Discovery, 2012
- US academic drug discoveryNature Reviews Drug Discovery, 2011
- Getting pharmaceutical R&D back on targetNature Chemical Biology, 2011
- Patents vs. Statutory Exclusivities in Biological Pharmaceuticals - Do We Really Need Both?SSRN Electronic Journal, 2011